menu
    • menu

    Company profile for Triumvira Immunologics

    NEW Drugs in Dev: 4
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technolog...
    Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Triumvira ImmunologicsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Crystal Mountain At Barton Creek, TX 78733
    Telephone
    Telephone
    512-790-0222
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://triumvira.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Triumvira Immunologics to Present Clinical Data at the 2024 ASCO
    Triumvira Immunologics to Present Clinical Data at the 2024 ASCO

    19 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/triumvira-immunologics-to-present-clinical-data-at-the-2024-asco-gastrointestinal-cancers-symposium-302018607.html

    PR NEWSWIRE
    19 Dec 2023
    Share Share
    Triumvira shares upcoming plans for accelerated approval with cell therapies
    Triumvira shares upcoming plans for accelerated approval with cell therapies

    14 Jun 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/triumvira-tac01-her2/

    CLINICAL TRIALS ARENA
    14 Jun 2023
    Share Share
    Triumvira Announces Updated Data from Ongoing TACTIC?2 Trial of TAC01-HER2
    Triumvira Announces Updated Data from Ongoing TACTIC?2 Trial of TAC01-HER2

    11 Nov 2022

    // BIOSPACE

    https://www.biospace.com/article/releases/triumvira-immunologics-announces-updated-data-from-ongoing-tactic-2-trial-of-tac01-her2-in-patients-with-her2-positive-solid-tumors/

    BIOSPACE
    11 Nov 2022
    Share Share
    Triumvira Demonstrates Strength of Preclinical Research Pipeline at SITC 2022
    Triumvira Demonstrates Strength of Preclinical Research Pipeline at SITC 2022

    10 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221109006125/en

    BUSINESSWIRE
    10 Nov 2022
    Share Share
    Triumvira Immunologics to Present Clinical and Preclinical Updates at SITC
    Triumvira Immunologics to Present Clinical and Preclinical Updates at SITC

    27 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221026006089/en

    BUSINESSWIRE
    27 Oct 2022
    Share Share
    Triumvira Appoints Life Sciences Industry Leader Robert Williamson as President
    Triumvira Appoints Life Sciences Industry Leader Robert Williamson as President

    25 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221024006042/en

    BUSINESSWIRE
    25 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search